Get the Stockscreener App
66.71
1.93%
1.26
Prestige Consumer Healthcare Inc stock is traded at $66.71, with a volume of 539.55K.
It is up +1.93% in the last 24 hours and down -12.69% over the past month.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
See More
Previous Close:
$65.45
Open:
$66.13
24h Volume:
539.55K
Relative Volume:
1.27
Market Cap:
$3.28B
Revenue:
$1.11B
Net Income/Loss:
$205.95M
P/E Ratio:
16.23
EPS:
4.11
Net Cash Flow:
$254.64M
1W Performance:
+2.65%
1M Performance:
-12.69%
6M Performance:
-21.17%
1Y Performance:
-5.91%
1-Day Range:
$65.70
$67.14
1-Week Range:
$64.48
$67.14
52-Week Range:
$62.95
$90.04
Prestige Consumer Healthcare Inc Stock (PBH) Company Profile
Name
Prestige Consumer Healthcare Inc
Sector
Phone
(914) 524-6800
Address
660 WHITE PLAINS RD., TARRYTOWN, NY
Compare PBH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBH
Prestige Consumer Healthcare Inc
|
66.71 | 3.19B | 1.11B | 205.95M | 254.64M | 4.11 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Prestige Consumer Healthcare Inc Stock (PBH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Downgrade | Sidoti | Buy → Neutral |
| Jun-21-24 | Upgrade | DA Davidson | Neutral → Buy |
| Nov-17-22 | Initiated | Canaccord Genuity | Buy |
| May-10-22 | Upgrade | Jefferies | Hold → Buy |
| May-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-07-20 | Downgrade | DA Davidson | Buy → Neutral |
| Jun-29-20 | Upgrade | Sidoti | Neutral → Buy |
| Apr-14-20 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-20 | Resumed | Sidoti | Neutral |
| Mar-26-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-24-20 | Initiated | Oppenheimer | Perform |
| Mar-19-20 | Upgrade | DA Davidson | Neutral → Buy |
| Jan-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-04-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-02-17 | Upgrade | Jefferies | Underperform → Hold |
| May-22-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-27-16 | Reiterated | B. Riley & Co. | Buy |
| Nov-17-16 | Initiated | Gabelli & Co | Buy |
| Aug-12-16 | Upgrade | Sidoti | Neutral → Buy |
| Mar-08-16 | Initiated | KeyBanc Capital Mkts | Overweight |
| Feb-05-16 | Initiated | Piper Jaffray | Overweight |
| Nov-30-15 | Downgrade | Jefferies | Hold → Underperform |
| Apr-28-14 | Reiterated | B. Riley & Co. | Buy |
| Apr-28-14 | Reiterated | Oppenheimer | Outperform |
| Jul-09-13 | Initiated | B. Riley & Co. | Buy |
View All
Prestige Consumer Healthcare Inc Stock (PBH) Latest News
Earnings call transcript: Prestige Consumer Healthcare Q1 2025 misses forecasts - Investing.com
Short Term Trend Reversal in Prestige Consumer Healthcare Inc. PossibleTrade Analysis Report & Low Drawdown Investment Ideas - beatles.ru
Resistance Break Could Fuel Prestige Consumer Healthcare Inc. Rally2025 Market Trends & Real-Time Sentiment Analysis - beatles.ru
Prestige Consumer Healthcare Inc. shares rise 1.29% intraday due to strong customer demand and operational excellence. - AInvest
CCORF Maintains Prestige Consumer Healthcare(PBH.US) With Buy Rating, Maintains Target Price $100 - 富途牛牛
What's the market missing about PBH's earnings potential? - AInvest
Is This a Bottoming Phase for Prestige Consumer Healthcare Inc.Market Activity Report & AI Forecasted Entry and Exit Points - beatles.ru
Prestige Consumer Healthcare Cuts FY22 Revenue Outlook Amid Supply Chain Issues and Retail Order Volatility - AInvest
Prestige Consumer Healthcare (PBH) Trims Outlook as Sales Dip—Is the Acquisition Strategy Still on Track? - simplywall.st
Prestige Consumer Healthcare’s Cautious Earnings Call Outlook - TipRanks
Prestige Consumer Healthcare's Strategic Acquisition and Q1 Earnings: A Value Investment Case in a Resilient OTC Sector - AInvest
Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its First-Quarter Earnings: Here's What Analysts Think - Yahoo Finance
Prestige Consumer Healthcare Acquires Pillar5 Pharma for Expansion - MSN
Prestige Consumer Healthcare: Analyst Maintains Buy Rating, Lowers Price Target to $100.00 - AInvest
Prestige Consumer Healthcare Inc. (NYSE:PBH) Q1 2026 Earnings Call Transcript - Insider Monkey
Prestige Consumer Starting Clear Eyes Production With No Contract Partner ‘Out There To Tap Into’ - insights.citeline.com
Prestige Consumer Healthcare's Q1 2026: Key Contradictions in Clear Eyes Supply, Market Share, and Margin Outlook - AInvest
Prestige Consumer Healthcare stock hits 52-week low at 64.83 USD By Investing.com - Investing.com South Africa
Prestige Consumer Healthcare stock hits 52-week low at 64.83 USD - Investing.com Nigeria
Prestige Brands stock price target lowered to $100 at Canaccord on eye care supply issues - Investing.com Canada
Prestige Consumer Healthcare's Strategic Path to Recovery: Can Shareholders Capitalize on a Turnaround in Eye Care and Margin Expansion? - AInvest
Prestige Consumer Healthcare: Fiscal Q1 Earnings Snapshot - Manistee News Advocate
Prestige Consumer Healthcare: Strategic Acquisitions and Innovation Drive Long-Term Value Creation - AInvest
Prestige Consumer Healthcare outlines $1.1B-$1.115B FY26 revenue target amid Pillar5 acquisition and Clear Eyes supply recovery - MSN
Prestige Consumer Healthcare 2026 Q1 Earnings Misses Targets as Net Income Falls 3.3% - AInvest
Prestige Consumer Healthcare Q1 Earnings and Strategic Acquisition of Pillar5 Pharma - AInvest
Prestige Consumer Healthcare’s Q1 Earnings and Strategic Moves - TipRanks
Prestige Earnings: Clear Eyes' Constraints Cloud Near-Term Outlook, but Core Portfolio Remains Solid - Morningstar
Prestige Consumer Healthcare Q1 2026 Earnings Call Transcript - MarketBeat
Prestige Consumer Healthcare shares fall 10.14% intraday after missing Q1 revenue estimates and lowering fiscal 2026 outlook. - AInvest
Prestige Consumer Healthcare Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Prestige Consumer Healthcare Inc. Q1 Profit Decreases, Misses Estimates - Nasdaq
Prestige Consumer Healthcare Plummets 10.5%: Earnings Shock and Sector Turbulence Ignite Sell-Off - AInvest
Prestige Consumer Healthcare (PBH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Prestige Consumer Healthcare's Strategic Acquisition of Anjac SAS: A Catalyst for OTC Men's Health Dominance - AInvest
Prestige Consumer Healthcare Eyes Growth Despite Revenue Shortfall - Finimize
Prestige Consumer Healthcare on Aug 4, unit entered agreement with Anjac SASSEC filing - MarketScreener
Prestige Consumer Healthcare Q1 FY26 slides: Revenue drops on supply issues, margins improve - Investing.com Nigeria
Prestige Consumer Healthcare Q1 FY26 slides: Revenue drops on supply issues, margins improve By Investing.com - Investing.com South Africa
Prestige Consumer Healthcare (PBH) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance
Prestige Consumer Healthcare Q1 Revenue Falls 6.6% Amid Supply Constraints and Order Timing Shifts - AInvest
Prestige Consumer Healthcare's Strategic Acquisition of Pillar5 Pharma: A Masterstroke in Supply Chain Resilience and Competitive Edge - AInvest
Prestige Consumer Healthcare Reports Lower Q1 Earnings Than ExpectedNews and Statistics - IndexBox
Prestige (PBH) Q1 Revenue Falls 6.6% - The Globe and Mail
Prestige Consumer's Strategic Turnaround: Assessing Brand Resilience and M&A-Driven Growth in a High-Margin Sector - AInvest
Prestige Consumer Healthcare Inc. SEC 10-Q Report - TradingView
Prestige Consumer misses Q1 revenue estimates, to acquire Pillar5 Pharma - MarketScreener
Prestige Consumer Healthcare's Fiscal 2026 Q1 Earnings: A Strategic Masterclass in Brand Diversification and Operational Excellence - AInvest
Prestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results - GlobeNewswire
Prestige Consumer Healthcare Inc Stock (PBH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):